<DOC>
	<DOCNO>NCT00007436</DOCNO>
	<brief_summary>The purpose study evaluate safety tenofovir disoproxil fumarate ( tenofovir DF ) combination anti-HIV drug patient participate tenofovir DF study ( GS-98-902 GS-99-907 ) , able tolerate drug different dos , may benefit tenofovir DF treatment .</brief_summary>
	<brief_title>The Safety Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs Treat HIV-Infected Patients</brief_title>
	<detailed_description>Patients take tenofovir DF combination antiretrovirals .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Have complete another study tenofovir DF without toxicity . Are willing use intrauterine effective barrier method birth control , men woman , study 30 day follow tenofovir DF treatment . Exclusion Criteria Patients eligible study : Are take drug may damage kidney ( nephrotoxic ) include aminoglycoside antibiotic , amphotericin B , cidofovir , cisplatin , foscarnet , IV pentamidine , vancomycin , oral IV ganciclovir . Are take agent affect kidney function , probenecid . Are receive systemic chemotherapy . Are take systemic corticosteroid . Are take experimental drug except approve Gilead . Are currently participate GS99908 GS00912 ( expanded access ) study . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>9- ( 2-phosphonylmethoxypropyl ) adenine</keyword>
</DOC>